Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | BTK inhibtors in CLL

Richard Furman • 10 Jun 2020
EHA 2020
B-Cell Lymphoma Chronic Lymphocytic Leukemia Leukemia Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Acalabrutinib ARQ 531 Ibrutinib Pirtobrutinib Vecabrutinib Zanubrutinib

Richard Furman, MD, of the Weill Cornell Medical College, New York, NY, updates us on the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL) as well as the development of third-generation BTK inhibitors that are currently in Phase II studies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Richard Furman

2:46
Combining B-cell receptor antagonists and venetoclax in CLL
Richard Furman • 10 Jun 2020
5:39
Acalabrutinib monotherapy in mature B-cell malignancies
Richard Furman • 10 Jun 2020
17:52
Diagnosis and Initial Treatment of CLL
Peter Hillmen et al. • 12 May 2017

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals